Haloperidol hydrochloride

Cat. No.: HY-14538A: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Haloperidol hydrochloride is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.

For research use only. We do not sell to patients.

Haloperidol hydrochloride Chemical Structure

CAS No. : 1511-16-6

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Haloperidol hydrochloride:

Haloperidol

Other Forms of Haloperidol hydrochloride:

Haloperidol In-stock
Haloperidol-d₄ Get quote
Haloperidol-d₄-1 Get quote
Haloperidol lactate Get quote

14 Publications Citing Use of MCE Haloperidol hydrochloride

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Dopamine Receptor Isoform Specific Products:

View All Isoforms

Dopamine Receptor D₁ Receptor D₂ Receptor D₃ Receptor D₄ Receptor D₅ Receptor

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Haloperidol hydrochloride is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.

In Vivo

Haloperidol (1 mg) intra-arterially attenuates the dopamine-induced pancreatic secretion. Haloperidol (3 mg) completely inhibits the action of 10 μg of dopamine in the pancreas of the dogs^[1]. Haloperidol (10 mg/kg) as well as chlorpromazine (CPZ, 15 mg/kg) blocks mescaline-induced altered behavior within 7 to 10 minutes when injected into the mice 45 minutes after 50 mg/kg (2 µc) of mescaline. Haloperidol has no effect on mescaline disappearance^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

412.33

Formula

C₂₁H₂₄Cl₂FNO₂

CAS No.

1511-16-6

SMILES

ClC(C=C1)=CC=C1C2(O)CCN(CCCC(C3=CC=C(F)C=C3)=O)CC2.Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Joy CB, et al. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003082. [Content Brief]

[2]. Giannini AJ, et al. Acute ketamine intoxication treated by haloperidol: a preliminary study. Am J Ther. 2000 Nov;7(6):389-91. [Content Brief]

Animal Administration
^[2]

Male albino mice of Swiss-Webster strain (33-36 g) are used, and all substances are given by i.p. injection in a volume of 0.5 mL. CPZ, haloperidoi and mescaline are all in time form of timeir imydrochlorides and the dose solutions are prepared at concentrations of 1.0, 0.66 and 3.3 mg/mL of 0.9% saline, respectively. The doses are: CPZ, 15 mg/kg; haloperidol, 10 mg/kg; mescaline, 50 mg/kg. Mice are pretreated with either CPZ or haloperidol 30 minutes before administration of mescaline. In some instances CPZ is injected 45 minutes after mescaline. Time animals are hmoused individually in a plexiglas cage and the gross behavior and locomotor activity. At selected intervals after mescaline, groups of mice are sacrificed by decapitation. Plasma is separated and stored at -20°C. The brain, liver, kidney, lung, spleen and heart are frozen on dry ice and stored at -20°C for 18 to 20 hours before they are used for assays.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Joy CB, et al. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003082. [Content Brief]

[2]. Giannini AJ, et al. Acute ketamine intoxication treated by haloperidol: a preliminary study. Am J Ther. 2000 Nov;7(6):389-91. [Content Brief]